Iain Stephenson

Summary

Affiliation: University Hospitals of Leicester
Country: UK

Publications

  1. ncbi Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Vaccine 21:1687-93. 2003
  2. ncbi Reproducibility of serologic assays for influenza virus A (H5N1)
    Iain Stephenson
    University of Leicester, UK
    Emerg Infect Dis 15:1252-9. 2009
  3. ncbi Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester, UK
    Clin Infect Dis 48:389-96. 2009
  4. ncbi Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study
    Iain Stephenson
    Infectious Diseases Unit, University Hospitals Leicester, Leicester LE1 5WW, UK
    Vaccine 25:4056-63. 2007
  5. ncbi H5N1 vaccines: how prepared are we for a pandemic?
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Lancet 368:965-6. 2006
  6. ncbi Influenza: current threat from avian influenza
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Br Med Bull 75:63-80. 2005
  7. ncbi Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009
    Iain Stephenson
    Dept of Infection, Inflammation and Immunity, University of Leicester, Leicester, United Kingdom
    Vaccine 28:3875-82. 2010
  8. ncbi Are we ready for pandemic influenza H5N1?
    Iain Stephenson
    Leicester Royal Infirmary, Level 6, Windsor Building, Leicester, LE1 5WW, UK
    Expert Rev Vaccines 4:151-5. 2005
  9. ncbi Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine
    Tristan W Clark
    Infectious Diseases Unit, University Hospitals Leicester, and Department of Inflammation, Infection and Immunity, University of Leicester, Leicester, United Kingdom
    N Engl J Med 361:2424-35. 2009
  10. ncbi Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, United Kingdom
    J Virol 80:4962-70. 2006

Collaborators

Detail Information

Publications26

  1. ncbi Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Vaccine 21:1687-93. 2003
    ..001). MF59 significantly increased GMTs of antibody when compared to non-adjuvanted vaccine (P<0.001)...
  2. ncbi Reproducibility of serologic assays for influenza virus A (H5N1)
    Iain Stephenson
    University of Leicester, UK
    Emerg Infect Dis 15:1252-9. 2009
    ..Sheep antiserum as a standard did not reliably reduce variability. The World Health Organization has established 07/150 as an international standard for antibody to clade 1 subtype H5 and has an assigned potency of 1,000 IU/ampoule...
  3. ncbi Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester, UK
    Clin Infect Dis 48:389-96. 2009
    ..We investigated the emergence of drug-resistant infection in children treated with a tiered weight-based dosing regimen...
  4. ncbi Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study
    Iain Stephenson
    Infectious Diseases Unit, University Hospitals Leicester, Leicester LE1 5WW, UK
    Vaccine 25:4056-63. 2007
    ..This study raises concern about comparability of serology results from H5N1 vaccine trials and it is proposed that an International Standard for influenza H5N1 antibody is developed...
  5. ncbi H5N1 vaccines: how prepared are we for a pandemic?
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Lancet 368:965-6. 2006
  6. ncbi Influenza: current threat from avian influenza
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Br Med Bull 75:63-80. 2005
    ..Oseltamivir has been stockpiled as part of influenza pandemic preparedness planning; however, the emergence of drug resistance may limit its clinical use...
  7. ncbi Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009
    Iain Stephenson
    Dept of Infection, Inflammation and Immunity, University of Leicester, Leicester, United Kingdom
    Vaccine 28:3875-82. 2010
    ..In addition, correlates of immune protection and regulatory issues for the evaluation and approval of future novel vaccine strategies were discussed...
  8. ncbi Are we ready for pandemic influenza H5N1?
    Iain Stephenson
    Leicester Royal Infirmary, Level 6, Windsor Building, Leicester, LE1 5WW, UK
    Expert Rev Vaccines 4:151-5. 2005
    ..Pandemic preparedness plans have been developed by national and international authorities but may be compromised by a lack of readily available interventions...
  9. ncbi Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine
    Tristan W Clark
    Infectious Diseases Unit, University Hospitals Leicester, and Department of Inflammation, Infection and Immunity, University of Leicester, Leicester, United Kingdom
    N Engl J Med 361:2424-35. 2009
    ..The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first pandemic of the 21st century. Development of effective vaccines is a public health priority...
  10. ncbi Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, United Kingdom
    J Virol 80:4962-70. 2006
    ..The addition of the biovector to the vaccine given with 30 microg LTK63 enhanced mucosal IgA responses to A/Duck/Singapore (H5N3) (P=0.0491) and B/Guandong (P=0.0028) but not to A/Panama (H3N2). All vaccines were well tolerated...
  11. ncbi Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations
    Karl G Nicholson
    Infectious Diseases Unit, University Hospitals Leicester, Leicester, LE1 5WW, UK
    Vaccine 28:171-8. 2009
    ..However, no vaccine formulation satisfied all European regulatory criteria for pandemic vaccines...
  12. ncbi Use of neuraminidase inhibitors to combat pandemic influenza
    Jane Democratis
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    J Antimicrob Chemother 58:911-5. 2006
    ....
  13. ncbi Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Lancet 362:1959-66. 2003
    ..Primed patients should be protected with a single dose of either vaccine...
  14. ncbi Enteric fever in a UK regional infectious diseases unit: a 10 year retrospective review
    Tristan W Clark
    Infectious Diseases Unit, Level 6 Windsor building, Leicester Royal Infirmary, Leicester LE15WW, UK
    J Infect 60:91-8. 2010
    ..Enteric fever is an increasingly common diagnosis in returning travellers in the UK...
  15. ncbi Clinical evaluation of vaccines for pandemic influenza H5N1
    Manish Pareek
    Infectious Diseases Unit, University Hospitals Leicester, Leicester LE1 5WW
    Br J Hosp Med (Lond) 68:80-4. 2007
    ..In 2004 the virus re-emerged among poultry and migratory birds in Asia and has spread into Europe and Africa, raising concerns that an H5 pandemic is imminent...
  16. ncbi Willingness of healthcare workers to accept voluntary stockpiled H5N1 vaccine in advance of pandemic activity
    Manish Pareek
    Infectious Diseases Unit, University Hospitals Leicester, Leicester LE1 5WW, UK
    Vaccine 27:1242-7. 2009
    ..A majority of healthcare workers are amenable to accept stockpiled H5N1 vaccine if offered in advance of pandemic activity...
  17. ncbi Antiviral treatment and prevention of seasonal influenza: a comparative review of recommendations in the European Union
    Iain Stephenson
    Infectious Diseases Unit, Level 6, Windsor Building, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester LE1 5WW, United Kingdom
    J Clin Virol 42:244-8. 2008
    ..Specific anti-influenza drugs are available for the management of seasonal influenza...
  18. ncbi Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1
    Iain Stephenson
    N Engl J Med 359:1631-3. 2008
  19. ncbi Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy
    Iain Stephenson
    Influenza Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Infect Dis 191:1210-5. 2005
    ..0004), and 43% (P = .0128) in 14 subjects, respectively, compared with 27%, 27%, 0%, and 0% in 11 who received nonadjuvanted vaccine. These findings have implications for the rational design of pandemic vaccines against influenza H5...
  20. ncbi Development and evaluation of influenza pandemic vaccines
    Iain Stephenson
    Lancet Infect Dis 6:71-2. 2006
  21. ncbi Confronting the avian influenza threat: vaccine development for a potential pandemic
    Iain Stephenson
    Influenza Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Lancet Infect Dis 4:499-509. 2004
    ..Adjuvanted or whole-virus preparations may improve immunogenicity and allow sparing of antigen...
  22. ncbi Seroprevalence of anti-H5 antibody among Thai health care workers after exposure to avian influenza (H5N1) in a tertiary care center
    Anucha Apisarnthanarak
    Infectious Diseases Division, Thammasart University Hospital, Klong Luang, Pratumthani, Thailand 12120
    Clin Infect Dis 40:e16-8. 2005
    ..There was no serologic evidence of anti-H5 antibody reactivity or subclinical infection in either of the groups...
  23. ncbi Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses
    Xiuhua Lu
    Influenza Branch, Centers for Disease Control and Prevention, USA
    Vaccine 24:6588-93. 2006
    ..These results demonstrated that vaccination of mice with H5 IIV or LAIV induced a high degree of cross-protection from illness and death following lethal challenges with a heterologous H5N1 virus...
  24. ncbi Development of vaccines against influenza H5
    Iain Stephenson
    Lancet Infect Dis 6:458-60. 2006
  25. ncbi Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice
    Mary A Hoelscher
    Influenza Branch, Division of Rickettsial and Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Lancet 367:475-81. 2006
    ..01). INTERPRETATION: Our findings highlight the potential of an Ad-vector-based delivery system, which is both egg-independent and adjuvant-independent and offers stockpiling options for the development of a pandemic influenza vaccine...
  26. ncbi Transmission of equine influenza virus to dogs
    P C Crawford
    College of Veterinary Medicine, University of Florida, Gainesville, FL 32611, USA
    Science 310:482-5. 2005
    ..Evidence of infection in pet dogs suggests that this infection may also become enzootic in this population...